Show simple item record

dc.contributor.authorMurphy, Mike
dc.contributor.authorHartley, Richard C
dc.date.accessioned2018-12-18T00:31:45Z
dc.date.available2018-12-18T00:31:45Z
dc.date.issued2018-12
dc.identifier.issn1474-1776
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/287068
dc.description.abstractAlthough the development of mitochondrial therapies has largely focused on diseases caused by mutations in mitochondrial DNA or in nuclear genes encoding mitochondrial proteins, it has been found that mitochondrial dysfunction also contributes to the pathology of many common disorders, including neurodegeneration, metabolic disease, heart failure, ischaemia-reperfusion injury and protozoal infections. Mitochondria therefore represent an important drug target for these highly prevalent diseases. Several strategies aimed at therapeutically restoring mitochondrial function are emerging, and a small number of agents have entered clinical trials. This Review discusses the opportunities and challenges faced for the further development of mitochondrial pharmacology for common pathologies.
dc.languageeng
dc.publisherSpringer Nature
dc.titleMitochondria as a therapeutic target for common pathologies.
dc.typeArticle
prism.endingPage886
prism.publicationNameNature Reviews Drug Discovery
prism.startingPage865
prism.volume17
dc.identifier.doi10.17863/CAM.34378
rioxxterms.versionofrecord10.1038/nrd.2018.174
rioxxterms.versionAM
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
dc.contributor.orcidMurphy, Mike [0000-0003-1115-9618]
dc.identifier.eissn1474-1784
rioxxterms.typeJournal Article/Review
pubs.funder-project-idMedical Research Council (MC_UU_00015/3)
pubs.funder-project-idWellcome Trust (110159/Z/15/Z)
pubs.funder-project-idMedical Research Council (MC_U105663142)
cam.issuedOnline2018-11-05
rioxxterms.freetoread.startdate2019-05-05


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record